GLP1R and Parkinson disease: In summary, CGRP-related pathways could prove to be novel targets in PD and other SAND therapeutics, as they contribute not only with their anti-inflammatory and anti-apoptotic properties, but also their positive metabolic effects on GLP-1 secretion, neuromodulation, and brain-gut communication.